Intratumoral PH-762 for Cutaneous Carcinoma

Squamous Cell Carcinoma of the Skin Clinical Trial

Official title:

Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06014086
• Other study ID #: PHIO-762-2301
• Status: Recruiting
• Phase: Phase 1
• Start date: November 7, 2023
• Est. completion date: September 2025

Study information

• Verified date: June 2024
• Source: Phio Pharmaceuticals Inc.
• Contact: Linda Mahoney
• Phone: 508-929-3601
• Email: lmahoney[@]phiopharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.

Description:

PH-762 is a potent RNAi molecule targeting PD-1. PH-762 can inhibit the immune checkpoint PD-1 in the tumor and thereby impede tumor growth. As a preoperative therapy, it may decrease the lesion size and has the potential to improve surgical morbidity. Intratumoral immunotherapy aims to use the tumor as a 'self-vaccine'. The local immune stimulation can induce robust priming of an anti-tumor immune response while generating systemic (abscopal) tumor responses, mediated by properly activated anti-tumor immune cells in the circulation. Local delivery of immunotherapy is expected to minimize systemic exposure and off-target toxicities.

This is a non-comparative study of neoadjuvant monotherapy using PD-1 targeting self-delivering RNAi (PH-762) in adult subjects with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The study treatment consists of four intratumoral injections of PH-762 at weekly intervals, into a single tumor lesion. Excision of the tumor will occur approximately two weeks following the fourth dose of IT PH-762, and the subjects will be followed for an additional 11 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Histologically confirmed cutaneous squamous cell carcinoma (cSCC), melanoma, or Merkel cell carcinoma, meeting one of the following criteria:

• cSCC, resectable local tumors: must be Stage II or lower, amenable to curative resection and in a location where acceptable surgical margins are anticipated

• cSCC, unresectable local tumors: must be Stage II or lower, tumor has been unresponsive to prior radiation therapy or is not a candidate for curative radiation therapy

• cSCC, metastatic disease: disease has progressed during or following prior checkpoint inhibitor therapy (anti-PD-1 or anti-PD-L1 antibody)

• Melanoma, metastatic disease: Stage IV disease with a cutaneous lesion that has progressed during or following checkpoint inhibitor therapy (anti-PD-1/-PD-L1), and if BRAF-mutation is present, has progressed during or following prior treatment with anti-BRAF + MEK therapy

• Merkel cell carcinoma, metastatic disease: Stage IV disease with a cutaneous lesion that has progressed during or following checkpoint inhibitor therapy (anti-PD-1/PD-L1)

• A minimum of one tumor of = 1.0 cm and < 3.0 cm in longest dimension that is accessible (with or without imaging guidance) for intratumoral injection and for biopsy and surgical excision must be present. The tumor is not necrotic, hemorrhagic, or friable, and is not within 2 cm of the eye or within 0.5 cm of or on the lip (including the vermilion border) and is not in a mucosal or visceral location.

Key Exclusion Criteria:

• Other malignancy within prior 3 years, with certain exceptions.

• Current cancer chemotherapy, radiation therapy, immunotherapy, or biologic therapy.

• Any serious or uncontrolled medical disorder including auto-immune disease that may increase the risk associated with study participation or study drug administration, or interfere with the interpretation of study results.

• Females who are pregnant or are breastfeeding.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Merkel Cell
• Carcinoma, Squamous Cell
• Malignant Melanoma of Skin
• Melanoma
• Squamous Cell Carcinoma of the Skin

Intervention

Drug:
• PH-762
PH-762 is a potent RNAi molecule targeting PD-1.

Locations

Country	Name	City	State
United States	Centricity Research	Columbus	Ohio
United States	Integrity Research	Delray Beach	Florida
United States	Banner MD Anderson Cancer Center	Gilbert	Arizona
United States	UPMC Department of Dermatology	Pittsburgh	Pennsylvania
United States	George Washington University	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Phio Pharmaceuticals Inc.	Prosoft Clinical

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events	Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events.	16 weeks
Secondary	Pharmacokinetics: maximum plasma concentration (Cmax)	Maximum concentration of PH-762 following intratumoral injection.	3.5 weeks
Secondary	Pharmacokinetics: time to maximum plasma concentration (Tmax)	Time to maximum concentration of PH-762 following intratumoral injection.	3.5 weeks
Secondary	Pharmacokinetics: area under the curve to last quantifiable plasma concentration (AUClast)	Exposure to PH-762 through last quantifiable concentration following intratumoral injection.	3.5 weeks
Secondary	Pathologic response	Pathological response will be assessed by relative amount of viable tumor in resection specimens of the treated lesion.	5 weeks
Secondary	Tumor burden	Change in tumor burden will be assessed per RECIST/ iRECIST guidelines for the treated lesion.	5 weeks